Navigation Links
GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA)

s regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.

GlaxoSmithKline Forward-Looking Statements

Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions investors that any forward-looking statements or projections made by the company, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the Operating and Financial Review and Prospects in the company's Annual Report on Form 20-F for 2005.

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R); HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM); HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.

Stock Exchange Release no. 27/2007

CONTACT: Contact: Helle Husted, Sr. Director, Investor Relations, T:+45-33-44-77-30, E: hth@genmab.com

Ticker Symbol: (:GNMSF)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
2. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
3. Genmabs HuMax-EGFr Shows Broad Potential in Cancer Treatment
4. The Past, Present and Future of HLA Typing
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
11. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/21/2014)...  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... (FDA) accepted the company,s Investigational New Drug (IND) application ... efficacy of AVP-786, Avanir,s next generation compound. The company ... adjunctive treatment of major depressive disorder (MDD) during the ... endorsement of this Phase II study by the division ...
(Date:7/21/2014)... 21, 2014 Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and its associated pain, ... the preclinical development of a small molecule inhibitor targeting ... The Myc protein has also been recognized as an ... is involved as a dominant factor in most human ...
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
Breaking Medicine Technology:Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces FDA Acceptance of IND for AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 2Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 3Sorrento Awarded Grant from the National Institutes of Health for the Development of a Small Molecule Myc Inhibitor 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5
... Inc. (OTCPK: SNDY) is pleased to announce that the Company ... in the amount of $90,005. The revenue for the three ... fifty Hospitals, Clinics, Healthcare Centers, Medical Centers and Surgery Centers ... growth in 2011 through new product development, new product sales ...
... Ireland, Jan. 27, 2011 Tibotec Pharmaceuticals today ... to generic manufacturers including Hetero Drugs Limited, Matrix ... Aspen Pharmacare of South Africa to manufacture, market ... rilpivirine hydrochloride (TMC278), pending ...
Cached Medicine Technology:Solos Endoscopy, Inc. Reports $90,005 in Sales Revenue for Fourth Quarter 2010 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 2Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 3Tibotec Signs Multiple Agreements With Generic Manufacturers to Provide Access to New HIV Treatment 4
(Date:7/22/2014)... (PRWEB) July 22, 2014 Garland’s new ... is designed to be used as a flood coat ... systems or as a premium restoration material. It provides ... the long-term performance and reducing life-cycle costs. Energizer BK ... to provide excellent water resistance in addition to superior ...
(Date:7/22/2014)... The hair transplant experts at WeGrowHair.com ... assisted laser therapy and robotic assisted hair transplantation ... women suffering from hair loss. Alongside their unique ... Unit Extraction (FUE) procedures via ARTAS – the ... technology, their doctors use advanced digital mapping to ...
(Date:7/21/2014)... sports in the United States, with more than 170,000 ... participation numbers, however, mean that more young people than ... and competition. , In a study published online today ... and available in an upcoming print issue, researchers from ... Children,s Hospital and the Colorado School of Public Health ...
(Date:7/21/2014)... July 21, 2014 As reported by ... Westin Hotel to Raise Addiction Awareness (7/15), thrill-seeking participants ... down a 27-story building in Downtown Philly. 100 people, ... event at the Westin Convention Center Hotel. Some of ... addiction. One man participated because his son killed himself ...
(Date:7/21/2014)... who have a clot in their legs and ... blood-thinning medication or undergo a minimally-invasive catheter-based clot ... no difference in death rates between the two ... the catheter procedure, according to a study by ... involved a review of more than 90,000 cases ...
Breaking Medicine News(10 mins):Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 2Health News:New study finds high school lacrosse players at risk for concussions, other injuries 3Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 2Health News:100 People Climb Down Building to Raise Drug Addiction Awareness in Philadelphia 3Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4
... international HIV and AIDS charity AVERT is today launching Stop ... to the 380,000 child AIDS deaths and half a ... ,At this year's G8 summit in Germany, the leaders ... to stop child AIDS deaths by committingspecific funds for prevention ...
... mental well being of young children of today seems to ... NCH, the childrens charity, found that one in ten ... significant level. ,The research says that More than a ... number in a generation. Emotional problems and conduct disorders have ...
... Washington University School of Medicine in St. Louis have ... by revealing that smoking interferes with ligament healing. ... model and found that cigarette smoking impairs the recruitment ... following ligament repair surgery. ,The researchers ...
... More than 60 people had to be treated in hospital ... a polluted Chinese river, state media reported Wednesday. ... their clothes in the Jindong River in eastern Anhui province ... few hours later, Xinhua news agency reported. ,The ...
... have found that a particular resonance pattern in the ... ability to discriminate speech. ,In the ... and Huan Luo report that the inherent rhythm of ... sentences by changing its phase. ,The researchers ...
... recalls how she lost her father, mother and father-in-law to ... to Panama from China. "It's very painful. The three had ... she says, her voice shaking with emotion. ,The ... found to be tainted. At least 80 people in Panama ...
Cached Medicine News:Health News:AIDS Charity AVERT Launches Stop AIDS in Children Campaign 2Health News:Mental Health of Children on the Decline 2Health News:Smoking Hampers Healing of the Ligament 2Health News:Dozens of Panamanians Gravely Ill from Toxic Substance from China 2